Abbott Gets FDA Approval for Heart-Rhythm Device
July 06 2020 - 8:10AM
Dow Jones News
By Matt Grossman
Abbott Laboratories has received approval from the Food and Drug
Administration for implantable devices for patients with
heart-rhythm disorders, the company said Monday.
The approval covers the company's cardioverter defibrillator and
resynchronization-therapy defibrillator devices. The devices
include Bluetooth technology and a smartphone app to improve
monitoring capability.
The devices are used to reduce the risks of arrythmias and
restore the heart's natural beating pattern if the heart's chambers
beat out of sync, Abbott said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 06, 2020 07:55 ET (11:55 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Apr 2023 to Apr 2024
